RYTHM 10-Q Details $20.6M Nine-Month Profit, $273M Licensing Backlog and $30M Debt Due Nov 22
RYM sits 18% above its 52-week low of $14 on elevated volume (2.3× avg).
Summary
RYTHM's Q3 10-Q shows $23.9 million of quarterly revenue and $48.2 million of cash, but the profit is a non-cash tax benefit and nearly all earnings come from a Green Thumb licensing deal that Green Thumb can repurchase once the December 11, 2026 THC restriction takes effect.
Key Events · Earnings and Guidance · RYM
-
Q3 Revenue $23.9M, Net Loss $0.5M
Revenue rose to $23.9 million from $4.0 million a year earlier, but the quarter produced a net loss of $0.5 million; nine-month net income of $20.6 million was driven by a $26.8 million non-cash tax benefit from releasing a valuation allowance.
-
Licensing Drives Nearly All Profit
Licensing Revenue was $17.5 million of the $23.9 million quarterly total versus $6.4 million of hemp product sales, and $273.4 million of contracted licensing fees remain to be recognized through August 27, 2030.
-
$30M Convertible Notes Due Nov 22
Total convertible notes are $80.0 million, with $30.0 million maturing November 22, 2026 including $27.0 million held by Green Thumb; the company says it is in active discussions on an extension and holds $48.2 million of cash.
-
Green Thumb Control and Buyback Option
Green Thumb is deemed to beneficially own about 89.9% of common stock and consolidates RYTHM from October 10, 2026; it also holds a call option on the MC Brands and VCP brand rights that becomes exercisable once the December 11, 2026 federal THC restriction takes effect.
Analysis · RYM · Industrial Applications And Services
The headline numbers were already out in this morning's 8-K, but the 10-Q fills in what actually drives the story. The $20.6 million of nine-month net income is almost entirely a $26.8 million non-cash tax benefit from releasing a valuation allowance, not operating profit — the quarter itself was a $0.5 million net loss. The real earnings engine is the amended Green Thumb licensing deal: $17.5 million of Q3 licensing revenue against $6.4 million of hemp product sales, with $273.4 million of contracted fees still to be recognized through 2030. Against that sits $80.0 million of convertible notes, $30.0 million of which matures November 22, 2026 and $27.0 million of that held by Green Thumb, which the company says it is negotiating to extend. The same December 11, 2026 federal THC restriction that threatens the hemp business also lets Green Thumb trigger its option to buy back the licensed brand rights — the asset generating nearly all the profit. Green Thumb is already deemed to own 89.9% and consolidates RYTHM from October 10, 2026, so minority holders are along for the ride on a controlled asset.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, RYM was trading at $16.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $36M. The 52-week trading range was $14.00 to $50.38. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.